Echo Fails The Test, OREX To Effect Reverse Split, PFE's S-TRAC Study Hits Goal

Gilead Sciences Inc.'s (GILD) Epclusa, a fixed-dose combination tablet containing sofosbuvir and velpatasvir, has been granted marketing authorization by the European Commission for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection. The drug was approved by the FDA on June 28, 2016.

from RTT - Biotech http://ift.tt/29GS0CH
via IFTTT